Stuart J. Mickel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stuart J. Mickel has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
Helmut Bittiger
10 shared publicationsRobert Daeffler
Chemical and Analytical Development, Novartis Pharma AG, CH 4002 Basel, Switzerland
7 shared publicationsWolfgang Froestl
7 shared publicationsDaniel Niederer
Division of Biomedical Marine Research, Harbor Branch Oceanographic Institution, 5600 U.S. 1 North, Fort Pierce, Florida 34946, and Chemical and Analytical Development, Novartis Pharma AG, Postfach 4052, Basel, Switzerland
6 shared publicationsAdnan Osmani
5 shared publicationsFrederick R. Kinder
5 shared publications
Latest Publications
- 1 January 2007
- Published by Walter de Gruyter GmbH in Pure and Applied Chemistry
- Vol. 79 (4) , 685-700
Total synthesis of the marine natural product (+)-discodermolide in multigram quantities
The novel polyketide (+)-discodermolide was isolated in very small quantities from sponge extracts. This compound is one of several microtubule stabilizers showing promise as novel chemotherapeutic agents for the treatment of cancer. The clinical evaluation of this and similar compounds is hampered by lack of material, and at present, the only way to obtain the necessary quantities is total chemical synthesis.
- 1 January 2007
- Published by Walter de Gruyter GmbH in Pure and Applied Chemistry
- Vol. 79 (4) , 685-700
Total synthesis of the marine natural product (+)-discodermolide in multigram quantities
The novel polyketide (+)-discodermolide was isolated in very small quantities from sponge extracts. This compound is one of several microtubule stabilizers showing promise as novel chemotherapeutic agents for the treatment of cancer. The clinical evaluation of this and similar compounds is hampered by lack of material, and at present, the only way to obtain the necessary quantities is total chemical synthesis.
- 19 April 2005
- Published by Wiley in ChemInform
- Vol. 36 (20)
Toward a Commercial Synthesis of (+)‐Discodermolide
For Abstract see ChemInform Abstract in Full Text.
- 19 April 2005
- Published by Wiley in ChemInform
- Vol. 36 (20)
Toward a Commercial Synthesis of (+)‐Discodermolide
For Abstract see ChemInform Abstract in Full Text.
- 1 November 2004
- Vol. 7 (6) , 869-81
Toward a commercial synthesis of (+)-discodermolide.
In this review some of the criteria required for a viable chemical (+)-discodermolide production process are discussed by critical evaluation of the available literature approaches. A further route involving the use of polyketide synthase to produce (+)-discodermolide fragments by fermentation is also described. Both approaches have advantages and disadvantages and require significant optimization in order to achieve commercialization of this important natural product.
- 1 November 2004
- Vol. 7 (6) , 869-81
Toward a commercial synthesis of (+)-discodermolide.
In this review some of the criteria required for a viable chemical (+)-discodermolide production process are discussed by critical evaluation of the available literature approaches. A further route involving the use of polyketide synthase to produce (+)-discodermolide fragments by fermentation is also described. Both approaches have advantages and disadvantages and require significant optimization in order to achieve commercialization of this important natural product.
- Open Access
- 1 September 2004
- Published by Swiss Chemical Society in Chimia
- Vol. 58 (9) , 640-648
Broad Spectrum Chemistry as Practised by Novartis Process Research
Three actual examples from the current product palette within Novartis Process Research will demonstrate the some of the variety and challenges encountered in modern chemical development.
- 1 September 2004
- Published by Swiss Chemical Society in Chimia
- Vol. 58 (9) , 640-648
Open AccessBroad Spectrum Chemistry as Practised by Novartis Process Research
Three actual examples from the current product palette within Novartis Process Research will demonstrate the some of the variety and challenges encountered in modern chemical development.
- 24 March 2004
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 67 (5) , 749-756
Synthetic Analogues of the Microtubule-Stabilizing Agent (+)-Discodermolide: Preparation and Biological Activity
A series of seven synthetic discodermolide analogues 2−8, which are minor side products generated during the final stages in the synthesis of (+)-discodermolide (1), have been purified and evaluated for in vitro cytotoxicity against A549, P388, MFC-7, NCI/ADR, PANC-1, and VERO cell lines. These synthetic analogues showed a significant variation of cytotoxicity and confirmed the importance of the C-7 hydroxy through C-17 hydroxy molecular fragment for potency. Specifically, these analogues suggested the relevance of the C-11 hydroxyl group, the C-13 double bond, and the C-16 (S) stereochemistry for the potency of (+)-discodermolide. The preparation, purification, structure elucidation, and biological activity of these new analogues are described.
- 24 March 2004
- Published by American Chemical Society (ACS) in Journal of Natural Products
- Vol. 67 (5) , 749-756
Synthetic Analogues of the Microtubule-Stabilizing Agent (+)-Discodermolide: Preparation and Biological Activity
A series of seven synthetic discodermolide analogues 2−8, which are minor side products generated during the final stages in the synthesis of (+)-discodermolide (1), have been purified and evaluated for in vitro cytotoxicity against A549, P388, MFC-7, NCI/ADR, PANC-1, and VERO cell lines. These synthetic analogues showed a significant variation of cytotoxicity and confirmed the importance of the C-7 hydroxy through C-17 hydroxy molecular fragment for potency. Specifically, these analogues suggested the relevance of the C-11 hydroxyl group, the C-13 double bond, and the C-16 (S) stereochemistry for the potency of (+)-discodermolide. The preparation, purification, structure elucidation, and biological activity of these new analogues are described.
- 4 December 2003
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 8 (1) , 122-130
Large-Scale Synthesis of the Anti-Cancer Marine Natural Product (+)-Discodermolide. Part 5: Linkage of Fragments C1-6 and C7-24 and Finale
- 4 December 2003
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 8 (1) , 122-130
Large-Scale Synthesis of the Anti-Cancer Marine Natural Product (+)-Discodermolide. Part 5: Linkage of Fragments C1-6 and C7-24 and Finale
- 4 December 2003
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 8 (1) , 107-112
Large-Scale Synthesis of the Anti-Cancer Marine Natural Product (+)-Discodermolide. Part 3: Synthesis of Fragment C15-21
- 4 December 2003
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 8 (1) , 107-112
Large-Scale Synthesis of the Anti-Cancer Marine Natural Product (+)-Discodermolide. Part 3: Synthesis of Fragment C15-21
- 4 December 2003
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 8 (1) , 101-106
Large-Scale Synthesis of the Anti-Cancer Marine Natural Product (+)-Discodermolide. Part 2: Synthesis of Fragments C1-6 and C9-14
- 4 December 2003
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 8 (1) , 101-106
Large-Scale Synthesis of the Anti-Cancer Marine Natural Product (+)-Discodermolide. Part 2: Synthesis of Fragments C1-6 and C9-14